Related Experiment Video
Updated: May 22, 2026
14:55
Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
Published on: December 3, 2013
Practical guidelines for producing non-replicating canine adenovirus vectors.
Denis Omara1,2,3, Christian Ndekezi1,2,3, Susan Mugaba3
1Uganda Virus Research Institute (UVRI), Entebbe, Uganda.
Plos One
|May 20, 2026
Summary
Canine adenovirus type 2 (CAV-2) vectors offer a promising alternative to human adenovirus type 5 (HAdV-5) for vaccine development due to low human seroprevalence. This protocol details the production of non-replicative CAV-2 vectors for translational research.
Area of Science:
- Virology
- Gene Therapy
- Vaccinology
Background:
- Adenovirus vectors are efficient gene delivery tools for vaccines and gene therapy.
- Human adenovirus serotype 5 (HAdV-5) use is limited by pre-existing immunity.
- Canine adenovirus type 2 (CAV-2) vectors present an alternative with low seroprevalence and efficient gene expression.
Purpose of the Study:
- To describe a protocol for producing non-replicative canine adenovirus type 2 (CAV-2) vectors.
- To provide methods for expression, expansion, purification, and titration of CAV-2 vectors.
- To facilitate the use of CAV-2 vectors in translational research.
Main Methods:
- Recombinant viral genome release from plasmid DNA.
- Virus stock expansion in AD-293 cells expressing E1 protein.
- Purification via ion-exchange chromatography and titration using Improved Kärber method.
Main Results:
- Successful production of a non-replicative CAV-2 vector.
- Established methods for purification and titration.
- Demonstrated feasibility of CAV-2 vector production.
Conclusions:
- CAV-2 vectors are a viable alternative for vaccine development and gene therapy.
- The described protocol enables efficient production of CAV-2 vectors.
- This work supports the advancement of alternative adenoviral vector applications.
